Overexpression of B7-H3 correlates with aggressive clinicopathological characteristics in non-small cell lung cancer

Wu, Shanshan; Zhao, Xiangfei; Wu, Sudong; Du, Rui; Zhu, Qingqing; Fang, Henghu; Zhang, Xinhong; Zhang, Chunyang; Zheng, Wei; Yang, Jiapeng; Feng, Hao

doi:10.18632/oncotarget.13177

Cited by 27 publications

(25 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…B7-H3 expression is significantly associated with poor outcome in patients with RCC (28–30), lung cancer (31), prostate cancer (32), CRC (33, 34), gallbladder cancer (35), esophageal squamous cancer (36), cervical cancer (37), osteosarcoma (OS) (38) and breast cancer (39). Thus, B7-H3 expression might be a feasible and effective means to predict the prognosis in cancer patients.…”

Section: B7-h3mentioning

confidence: 99%

New B7 Family Checkpoints in Human Cancers

Dong

2017

Molecular Cancer Therapeutics

198

201

View full text Add to dashboard Cite

T cells are the main effector cells in immune response against tumors. The activation of T cells is regulated by the innate immune system through positive and negative costimulatory molecules. Targeting immune checkpoint regulators such as programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) has achieved notable benefit in a variety of cancers, which leads to multiple clinical trials with antibodies targeting the other related B7/CD28 family members. Recently five new B7 family ligands, B7-H3, B7-H4, B7-H5, B7-H6 and B7-H7, were identified. Here we review recent understanding of new B7 family checkpoint molecules since they have come to the front of cancer research with the concept that tumor cells exploit them to escape immune surveillance. The aim of this article is to address the structure and expression of the new B7 family molecules as well as their roles in controlling and suppressing immune responses of T cells as well as NK cells. We also discuss clinical significance and contribution of these checkpoint expressions in human cancers.

show abstract

Section: B7-h3mentioning

confidence: 99%

New B7 Family Checkpoints in Human Cancers

Dong

2017

Molecular Cancer Therapeutics

198

201

View full text Add to dashboard Cite

show abstract

“…This mutation is within a conserved domain, as reported by Uniprot, that is Ig-like C2-type 1domain, and we could speculate that the substitution of a hydrophobic aminoacid with an electrically positive charged one could impair the functionality of B7-H3 protein.In the last years, such gene has been investigated revealing a key role in immune escape in cancer. Moreover, B7-H3 is able to induce anti-apoptotic and proliferative effects [21].…”

Section: Discussionmentioning

confidence: 99%

Molecular Characterization of a Long Term Survivor Double Metastatic Non Small Sell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy

Brunetti¹,

Badalamenti²,

Summa³

et al. 2019

Preprint

View full text Add to dashboard Cite

Management of multiple primary cancers, a not so infrequent event in oncology practice, is a critical issue due to the lack of literature . In this study, we reported the case of a patient with metachronous double metastatic non small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) who received gefitinib in combination with gemcitabine plus nab-paclitaxel and with mFOLFOX6 in first and second line, respectively. She achieved a progression free survival and an overall survival (OS) of 28 months for NSCLC and PFS-1 and OS of 20 and 13 months, respectively for PDAC. Moreover, the combination of gefitinib and chemotherapies treatments displayed a good safety profile. Given the insignificant frequency of this case, we performed a molecular characterization of both neoplasms with the aim to investigate the existence of particular activated pathways and/or similar immunological mutations. it is interesting to note that two neoplasms shared a commune mutation of B7-H3 gene, with the consecutive impairment of its expressed protein. In both PDAC and NSCLC, the expression of this protein was associated with a worse survival. Since B7-H3 is an anti-apoptotic protein, the reduction of its expression or function should justify a pro-apoptotic activity with a putative justification of the long survival of the patient considered in this report.

show abstract

“…Lina Wu et al [37] 2017 NSCLC Lymph node MicroRNA-422a Chu Y et al [38] 2017 Adenocarcinoma Lymph node CLSTN1, CLU, NGAL Brody R et al [39] 2017 NSCLC NS PD-L1 Wu S et al [40] 2016 NSCLC Lymph node B7-H3 Chen Y et al [41] 2015 NSCLC Brain NSE Jain L et al [42] 2009 NS NS SNP Oshiro Y et al [43] 2004 Adenocarcinoma Liver AFP Nikliński J et al [44] 1992 NSCLC Lymph node SCC Hirashima T et al [45] 2000 NSCLC NS telomere…”

Section: Metastatic Sites Risk Factormentioning

confidence: 99%

CA-125, CA-153, and CYFRA21-1 as clinical indicators in male lung cancer with ocular metastasis

Li¹,

Yuan²,

Zou³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Despite recent improvements in diagnosis and therapy, lung cancer remains the most common malignant tumor in males, with high morbidity and mortality. As the annual incidence continues to increase worldwide, the prognosis for male patients with lung cancer remains unsatisfactory. Interestingly, smoking is associated with lung cancer and ocular lesions by altering risk factors such as carbohydrate antigen (CA)-125, CA-153 and cytokeratin-19 fragment (CYFRA21-1). A diagnostic standard for serum biomarker levels of ocular metastasis (OM) in males with lung cancer is therefore urgently needed. In this retrospective analysis, we examined the relationship between smoking preference and OM in male patients with lung cancer to identify an independent prognostic factor or establish a quantitative indicated standard for OM using the clinical indexes from 2238 cases of male lung cancer. The combination of CA-125, CA-153 and CYFRA21-1 could help diagnose OM in male lung cancer patients. This finding might lead to more timely diagnosis and effective therapies.

show abstract

Overexpression of B7-H3 correlates with aggressive clinicopathological characteristics in non-small cell lung cancer

Cited by 27 publications

References 37 publications

New B7 Family Checkpoints in Human Cancers

New B7 Family Checkpoints in Human Cancers

Molecular Characterization of a Long Term Survivor Double Metastatic Non Small Sell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy

CA-125, CA-153, and CYFRA21-1 as clinical indicators in male lung cancer with ocular metastasis

Contact Info

Product

Resources

About